The significance of the polymerase chain reaction (PCR) in the detection of minimal residual disease in Philadelphia chromosome (Ph')-positive chronic myelogenous leukemia (CML) following interferon therapy was investigated. Forty remission blood samples obtained at various remission time points from 29 patients in complete cytogenetic remission were analyzed. All 40 samples showed minimal residual Ph'-positive cells by PCR: 22 in remission for less than 12 months, 12 in remission for 12 to 24 months, four in remission for 25 to 60 months, and two in remission for more than 60 months. Of these 29 patients, seven relapsed at 4,6,9,14,17, HILADELPHIA chromosome (Ph')-positive chronic P myelogenous leukemia (CML) is a pleuripotent stem cell disease characterized by two distinct clinical phases: an initial chronic phase lasting for 2 to 4 years, followed by a fatal blastic crisis.',* Previous therapy using single-agent chemotherapy, as well as combination chemotherapy, failed to achieve a sustained suppression of Ph'.3.4 The advent of allogeneic bone marrow transplant and interferon therapy has resulted in durable complete clinical and cytogenetic remi~sion.',~ However, disease recurrence and progression remains a major problem. Relapse from subclinical minimal residual disease is the most likely mechanism.
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The polymerase chain reaction (PCR) is a molecular technique that permits the detection of neoplastic cells with a chromosomal translocation at a level less than one in lO0,OOO.' This assay provides a unique opportunity to explore the biology of minimal residual disease in patients who are thought to be in complete remission. Ph' in CML involves a reciprocal translocation of the BCR gene and c-ab1
Depending on where the chromosomal breakpoint at the bcr region occurs, the fused BCRlabl gene transcribes into one of two types of chimeric BCRlabl transcripts: L-6 (bcr exon I1 and c-ab1 exon "2" linkage or b2/a2 linkage) or K-28 (bcr exon 111 and c-ab1 exon "2" linkage or b31a2 linkage)." Taking advantage of these unique molecular characteristics, we and others have previously reported that PCR facilitates specific identification of the chimeric BCRlabl messages at a highly sensitive level."^'' We have reported in a small series that the complete cytogenetic responders following interferon therapy still harbor small numbers of Ph'-positive cells. '5 In this report, we studied a larger number of patients with longterm clinical follow-up to address the significance of PCR in the detection of minimal residual disease in Ph'-positive CML following interferon therapy.
MATERIALS AND METHODS
Patient characterization and sample procurement. Twenty-nine patients who were diagnosed with Ph'-positive CML and who had achieved complete clinical and cytogenetic remission for at least 6 months entered this study. Of these 29 patients, 19 were treated with interferon-alpha alone, four were treated with interferonalpha and hydrea, and the remaining six were treated with a combination of interferon-alpha and interferon-gamma as previously described.6.16 Forty peripheral blood samples were obtained at various time points of complete cytogenetic remission ranging from 3 to 68 months. The blood samples were subjected to PCR analysis. Bone marrow samples were obtained simultaneously for karyotypic analysis. Approval was obtained from the Institutional Review Board for these studies. Informed consent was provided according to the declaration of Helsinki.
Periodic karyotypic analyses were performed as previously described" in the bone marrow samples every 3 to 6 months. At least 20 metaphases were examined in each analysis. Complete cytogenetic remission was defined by the complete absence of Ph'-positive cells in at least two consecutive studies 3 months apart. Disease recurrence. was defined by reappearance of Ph'-positive cells with or without changes in hematologic examination.
Detection of the chimeric BCRlabl mRNAs by PCR was performed as we previously described." In brief, an antisense oligonucleotide, primer abl( -), derived from the sequence of the second exon of the c-ab1 oncogene was used to synthesize the first strand cDNAs from the total RNA samples. Another oligonucleotide derived from the second exon of the bcr region, primer bcr( +), was then added along with Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT) and PCR buffer. PCR was performed in a Thermocycler (Perkin-Elmer Cetus) for 50 cycles by a modification of the method described previously.'' Ten microliters of PCR amplified products was loaded onto a 3% NuSieve agarose gel and size fractionated at 60 V for 5 hours and then transferred to a nylon membrane after denatur- For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
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ation. The membrane was hybridized with a mixture of 5'-end radiolabeled probes L-6 and K-28, which were derived from the sequences at the BCRlabl junctions of L-6 (b2/a2) and K-28 (b3/a2) mRNAs, respectively. The membrane was then washed with 2x SSPE (sodium chloridelsodium phosphate/ethylenedramine tetraacetate)/O.l% sodium dodecyl sulfate (SDS) at room temperature for 60 minutes and at 60°C for another 15 minutes. Autoradiography was performed against a single intensifying screen at -70°C for 4 to 48 hours. Special precautions to prevent contamination while performing PCR were undertaken as previously described."' Furthermore, PCR was performed in duplicate to ensure the consistency of the results. In the presence of L-6 (b2/a2) mRNA, a cDNA fragment of 80 bp was detected. In the presence of K-28 (b3/a2) mRNA, a 155-bp fragment was detected.
Since the PCR was performed in duplicate, discordant results were observed occasionally. In such cases, we repeated the analysis by adding another oligonucleotide primer cab/( +). 5'-'ITGGAGATC-TGCCTGAAGCT-3' (derived from the exon la of the c-abl gene), in our PCR reaction to coamplify the c-abl, as well as the BCRlabl transcripts in the same PCR reaction. The amplified c-ab/ fragment was expected to be 110 bp in size. The amplification of the c-ab/ fragment allowed us to indirectly evaluate the integrities of our RNA samples and the efficiency of PCR, which in turn avoided false-negative results.
RESULTS
Forty remission blood samples were analyzed hy PCR for the presence of minimal residual chimeric BCRlabl transcripts. These samples were obtained at various time points of complete cytogenetic remission: 22 in remission for less than 12 months, 12 in remission for 12 to 24 months, four in remission for 25 to 60 months, and two in remission for more than 60 months, All of these 40 samples (from 29 patients) showed PCR-positivity with various degrees of intensity (Fig 1 and Table 1 ). Of these 29 patients, there was heterogeneity in the type of chimeric messages detected: 17 had an L-6 (b2/a2) message, l l had a K-28 (b3/a2) message, and one had both messages (Fig 1 and  Table 1 ). Sequential follow-up samples during remission were available in eight patients ( Table 1 , patients no. 6, 9, 15, 17,20,23,24, and 26). None of these eight patients had conversion of PCR-positivity to PCR-negativity or changes in the type of chimeric messages during remission. Of the 29 patients, seven (four with L-6, two with K-28, and one with both messages) relapsed at 4,6,9,14, 17.19, and 50 months after their first PCR-positivity with the duration of remission lasting for 7, 9, 33, 17, 20, 24, and 53 months, respectively (Table 1 , patients no. 21, 29, 2, 28, 6, 5, 17, respectively). One (with L-6 message) developed hepatosplenomegaly with extramedullary myelopoiesis at 49 months after the first PCR-positivity (Table 1, patient 13). The remaining 21 patients (12 with L-6 and nine with K-28) remained in complete hematologic and cytogenetic remission with a median follow-up of 13 months (range, 4 to 36 months) after their first PCR analysis. Strikingly, two samples from patient 15 obtained at 65 and 68 months of remission, respectively, showed persistent PCR-positivity even though interferon treatment had been discontinued for more than 24 months. 
DISCUSSION
PCR is extremely sensitive in detecting minimal residual Ph'-positive cells in complete cytogenetic responders. However, the clinical and biological significance of PCRpositivity has yet to be explored. To address this specific question, we studied a large number of complete cytogenetic responders following interferon therapy with longterm clinical follow-up.
We observed PCR-positivity in 40 of 40 samples obtained at various time points of complete clinical and cytogenetic remission, suggesting that interferon therapy does not completely eradicate Ph'-positive cells. Interestingly, two of these samples were analyzed at the time when the patient had been in remission for more than 60 months (patient 15, Table 1 ). This suggests that minimal residual Ph'-positive cells can be present for a very long time without the imminent possibility of disease recurrence. Nevertheless, we noted that disease recurrence in some patients (as late as 50 months after the first PCR-positivity) eventually occurred. This finding raises an interesting question as to whether the minimal residual Ph'-positive cells can be kept quiescent for a long time and then reactivated at a later time.
Twenty-one of the 29 patients we studied remained in complete hematologic and cytogenetic remission with median follow-up of 13 months (range, 4 to 36 months) after their first PCR-positivity. Since we have observed late disease recurrence, it will not be surprising that at least some of these patients will eventually relapse after longterm clinical follow-up. It is not unreasonable to hypothesize that a patient with a high percentage of actively proliferating Ph'-positive cells will relapse earlier. Therefore, in the future it will be more meaningful to know if PCR-positivity is observed in dividing cells (cells sorted in the S phase of the cell cycle) or in cells with self-renewal capability (cells harvested by colony assay). Such a biologydirected PCR assay may help define the proliferative potential of the residual Ph'-positive cells in the remission samples and eventually help predict disease recurrence in an early stage.
PCR has also been applied to the detection of minimal residual disease in Ph'-positive CML following allogeneic bone marrow transplant. The results have been contradictory. 2023 Gabert et a1 reported that 11 of 12 patients in complete cytogenetic remission showed minimal residual disease and three patients had been well for more than 5 years after transplant.*' However, lower frequencies of PCR-positivity have been observed by other investigators.*' 23 Recently, Hughes et a1 reported that 18 complete cytogenetic responders at 8 months to 8 years posttransplant were all PCR-negative and suggested that PCR results might have prognostic significance.u However, Pignon et a1 reported that 16 of 17 patients studied were PCRpositive.*' Snyder et a1 observed 13 PCR-positivities in 19 patients in remission after transplant and only one patient had relapsed.26 There could be many possible explanations for these discrepancies, including that the PCR assay has not yet been standardized. Different investigators are using different PCR programs, different PCR primers, different numbers of PCR cycles, and different methods to avoid cross-contamination, Since long-term clinical follow-up after PCR analysis is not available, the clinical significance of these observations remains unclear. Questions should be addressed in the future are: do the PCR-negative patients remain in remission and do the PCR-positive patients eventually relapse? Since we have observed late recurrence several years after PCR-positivity, long-term clinical follow-up is important to accurately access the significance of PCR assay.
